Harbour Biomed (guangzhou) Co. Ltd.

This study tested a weekly injection called HBM9161 in 36 adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. Participants had failed at least one prior treatment. The goal was to see if the drug could …

This study looked at the long-term safety of a drug called HBM9161 for people with generalized myasthenia gravis, a condition that causes muscle weakness. Over 100 patients who had already completed an earlier study received the drug as a shot under the skin. Researchers tracked …